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In the federal rules governing research (the “CommonRule”), 45CFR46, Section 46.114 reads:
§46.114 Cooperative research.
Cooperative research projects are those projects cov-
ered by this policy which involve more than one institu-
tion. In the conduct of cooperative research projects, each
institution is responsible for safeguarding the rights and
welfare of human subjects and for complying with this
policy. With the approval of the department or agency
head, an institution participating in a cooperative project
may enter into a joint review arrangement, rely upon the
review of another qualified IRB, or make similar arrange-
ments for avoiding duplication of effort.
The federal rules cover any research funded by var-
ious federal agencies or any research on new drugs or
devices. The issue with this language is that although it
seeks to promote a single review, it requires every insti-
tution to be responsible for the welfare of human sub-
jects. This has been understood by individual institu-
tional review boards (IRBs) to mean that each must
conduct it own full review. As more studies are done at
numerous sites, this results in multiple IRB review of
single protocols.
Ravina et al argue in their article on local IRB re-
view of multicenter trials that individual reviews at mul-
tiple sites add substantial costs without substantial bene-
fit.1 They estimate review costs of approximately
$107,544 in direct costs plus $82,610 in fees and
$24,934 in labor. They show that individual reviews only
resulted in minor, nonsignificant changes, such as the ad-
dition of each local IRB’s preferred standard consent form
language on standard clauses. There is no evidence that
these minor changes make any difference in a subject’s
decision to participate.2
The authors found no important changes to the
study protocol. They conclude that individual review re-
sults in significant expense and time for a very small re-
turn.1
Because an important goal of IRB review is protec-
tion of human subjects, a central review seems better for a
detailed safety and risk–benefit review. If a second goal is
an understandable study with clear information to enable
a prospective participant to decide whether to enroll,
again a central review could best design an understandable
standardized consent process and form. If a third goal is
to be sure that local investigators are qualified and local
enrollment approaches are not coercive, there would be a
role for local review limited to local issues. However, the
Ravina study shows that local IRBs do not have a major
focus on local issues.
Local IRBs are increasingly overburdened, leaving
them insufficient time to concentrate on significant local
issues like participant recruitment, local researcher quali-
fications, and local safety. Use of a central IRB could al-
low local IRBs more time to concentrate on issues of local
importance.3
The US Food and Drug Administration (FDA) has
issued guidance on using a centralized IRB for multi-
center trials.4 The guideline points out the substantial
growth over time in multicenter studies and the conse-
quent needless duplication of effort by individual IRBs
at each center, resulting in increased expenses. Although
the FDA recognizes the need to consider local aspects of
review, it suggests that a centralized IRB review could
include consideration of local factors by consulting with
the local IRB or allowing limited local IRB review.
IRBs ought to have sufficient time to review proto-
cols to be sure human subjects are protected. They should
not duplicate efforts of other equally qualified IRBs, nor
should they impose their own versions of boilerplate lan-
guage in consent forms on other IRBs. It would be pref-
erable to establish a template for items like the injury
clause, who to contact with questions, and how to with-
draw from a study. Indeed, in cancer drug protocols, a
central IRB should be in a better position to determine
the safest way to withdraw, rather than having each local
IRB write its own language.
It may be that the Office of Human Research Pro-
tection (OHRP) oversight has caused local IRBs to be
nervous about ceding review to a central IRB, but if the
goal is to protect subjects, then the proper local IRB anal-
ysis must focus on what protection is being lost by a cen-
tral board review.
A full solution to overburdened IRBs will involve
new OHRP rules, templates for consent forms, minimal
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review for minimal-risk protocols, extended review periods,
and other changes to the current system. Central review
supported by the OHRP could, as the authors suggest, be
an important improvement element. It would be useful for
the OHRP to finalize its proposed rule change, making it
easier for multicenter studies to rely on a central IRB re-
view.
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